Arbutus Biopharma Corporation
ABUSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeArbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. With a market capitalization of $916.6M, it sits in small-cap territory. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
Market Cap
$916.6M
Beta
0.62
P/E (TTM)
5.59
P/E (Fwd)
-28.07
EPS (TTM)
$0.83
EPS (Fwd)
$-0.17
ROE
94.7%
ROA
49.2%
Cash
$95.2M
Total Debt
$3.9M
Free CF
-$90.4M
52W Change
34.9%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $95.2M in cash comfortably exceeding the $3.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$90.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of 94.7% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 49.2% further supports the picture of efficient asset utilization. Revenue has pulled back from $39.0M (2022) to $14.1M (2025), a 64% decline worth watching.
With a beta below 0.7, Arbutus Biopharma Corporation typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, ABUS has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing ABUS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.